Whats new
Whats new.
Ladenburg Thalmann - Efti is Making Keytruda Work in PD-L1 Negative Patients in Head and Cancer; Rated Buy, US$8.30 PT (Analyst: Ahu Demir, PhD)
July 12th 2024
For a copy of this research report please contact your Ladenburg Thalmann advisor